Multivalent Benzamidine Molecules for Plasmin Inhibition: Effect of Valency and Linker Length

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Enzyme Inhibition

Background:

• Emerging interest in synthetic multivalent inhibitors for strong and selective enzyme inhibition.
• Plasmin, an enzyme crucial for blood clot digestion, is a target for treating bleeding disorders.
• Benzamidine serves as a reversible inhibitor for plasmin's active site.

Purpose of the Study:

• To investigate the impact of valency and linker length on multivalent benzamidine inhibitors targeting plasmin.
• To systematically synthesize and evaluate inhibitors with varying valencies (mono-, bi-, tri-valent) and linker lengths (1-12 nm).

Main Methods:

• Synthesis of multivalent benzamidine inhibitors with controlled valency and linker length.
• Enzyme inhibition assays using a plasmin substrate (S-2251).
• Determination of inhibition constants (Ki) to quantify inhibitor potency.

Main Results:

• Pentamidine (bivalent) and Tri-AMB (trivalent) demonstrated the highest inhibitory potency with Ki values of 2.1±0.8 μM and 3.9±1.7 μM, respectively.
• Increased inhibitor valency and decreased linker length led to enhanced plasmin inhibition.
• Statistical rebinding effects were observed, increasing the effective local concentration of inhibitors.

Conclusions:

• Multivalent inhibitor design can be optimized by modulating valency and linker length for enhanced enzyme inhibition.
• This study provides insights for designing potent and selective multivalent inhibitors for therapeutic applications.
• Understanding the interplay between valency and linker length is key to developing effective enzyme-targeting drugs.